ライフサイエンスコーパス: cannabidiol

1 articularly Delta-9-tetrahydrocannabinol and cannabidiol.

2 a(2+) store-dependent component sensitive to cannabidiol.

3 these parameters following administration of cannabidiol.

4 2-arachidonoylglycerol, methanandamide, and cannabidiol.

5 eriving synthetically from readily available cannabidiol.

6 stimates for Delta9-tetrahydrocannabinol and cannabidiol.

7 ition of resurgent and persistent current by cannabidiol.

8 mphasis on Delta(9)-tetrahydrocannabinol and cannabidiol.

9 ns of Delta(9) tetrahydrocannabinol (THC) or cannabidiol.

10 ne, is blocked by SR141716A (1 microM) or by cannabidiol (10 microM).

11 Interventions included purified cannabidiol (11 [47.8%]), nabilone (4 [17.4%]), tetrahyd

12 Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase leve

13 Hypotension by Abn-cbd is also inhibited by cannabidiol (20 microgram/g), which does not influence a

14 Cannabidiol, 300 mg (150 mg twice per day), plus standar

15 ed using tetrahydrocannabinol (587 [36.9%]), cannabidiol (537 [33.7%]), melatonin (438 [27.5%]), caff

16 eded by the ingestion of Delta9-THC (10 mg), cannabidiol (600 mg), or placebo in a double-blind, rand

17 (195-mg cannabidiol, 63 participants; 390-mg cannabidiol, 62 participants; placebo, 63 participants).

18 re randomized, treated, and analyzed (195-mg cannabidiol, 63 participants; 390-mg cannabidiol, 62 par

19 By spiking abnormal cannabidiol, a cannabinoid not naturally present in hemp

20 deletion of GPR55 or by the GPR55 antagonist cannabidiol, a constituent of Cannabis sativa.

21 Glutamate toxicity was reduced by both cannabidiol, a nonpsychoactive constituent of marijuana,

22 The cannabinoid analog abnormal cannabidiol [abn-cbd; (-)-4-(3-3,4-trans-p-menthadien-[1

23 The cannabinoid analog "abnormal cannabidiol" (abn-cbd) causes endothelium-dependent vaso

24 Here we show that "abnormal cannabidiol" (Abn-cbd) is a neurobehaviorally inactive c

25 g approximately 40 fold more potent than (+)-cannabidiol; abnormal-cannabidiol is a full agonist.

26 e genes, which are responsible for producing cannabidiol acid and delta-9-tetrahydrocannabinolic acid

27 It was found that THC and cannabidiol act as type I ligands and induce a nearly co

28 her, the results from this study reveal that cannabidiol, acting through CB2 and regulation of Nox4 a

29 ve-like and anxiety-like behaviour, although cannabidiol administration suggests a role of additional

30 Chronic cannabidiol administration was well-tolerated, high leve

31 of GPR18, including anandamide and abnormal cannabidiol, also failed to induce inhibition of calcium

32 The cannabidiol analog O-1918 does not bind to CB(1) or CB(2

33 This potentiation was abolished by the cannabidiol analog O-1918 or by pertussis toxin but was

34 patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08).

35 in convulsive-seizure frequency was 43% with cannabidiol and 27% with placebo (odds ratio, 2.00; 95%

36 hat moderate- to high-value compounds (i.e., cannabidiol and artemisinin) offer net economic benefits

37 pophilic fraction containing 0.2 and 2.2g of cannabidiol and cannabidiolic acid per 100g of threshing

38 )-trans-Delta(9)-tetrahydrocannabinol (THC), cannabidiol and cannabinol, and a muscarinic receptor bl

39 f urinary Delta9-tetrahydrocannabinol (THC), cannabidiol and cannabinol, and two major metabolites of

40 certain plant-derived cannabinoids, such as cannabidiol and Delta9-tetrahydrocannabivarin, which are

41 ve peaks as high as 74%, as was the case for cannabidiol and interference #1 at 70 mus gate pulse wid

42 of substituted phenols were used to prepare cannabidiol and linderatin derivatives, and their struct

43 The neuroprotective actions of cannabidiol and other cannabinoids were examined in rat

44 difference in efficacy was observed between cannabidiol and placebo during the double-blind treatmen

45 sensitivies without reducing sensitivity to cannabidiol and probenecid.

46 binoid levels by use of the phytocannabinoid cannabidiol and selective fatty acid amide hydrolase inh

47 Cannabidiol and THC also were shown to prevent hydropero

48 The neuroprotection observed with cannabidiol and THC was unaffected by cannabinoid recept

49 to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median

50 polyhydroxybutyrate [PHB]), $10 to $100/kg (cannabidiol), and >$100/kg (artemisinin).

51 inoids, namely, Delta9-tetrahydrocannabinol, cannabidiol, and cannabinol.

52 : eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate.

53 s eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate.

54 , mice treated with the antiseizure medicine cannabidiol, and plasma from patients with treatment-res

55 ivators that bind at different sites: 2-APB, cannabidiol, and probenecid.

56 elta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabidiol, and terpenes.

57 8%) included tetrahydrocannabinol; 33 (56%), cannabidiol; and 8 (14%), both.

58 These findings suggest that Abn-cbd and cannabidiol are a selective agonist and antagonist, resp

59 roposed, and the antipsychotic properties of cannabidiol are currently being investigated in humans.

60 Conolidine and cannabidiol are plant-derivatives with known antinocicep

61 ying neurons, we propose that cannabinol and cannabidiol are promising nonpsychotropic therapeutics t

62 Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol, are increasingly being used to treat a vari

63 e, aprepitant, nortriptyline, buspirone, and cannabidiol as first-line therapies.

64 es per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14

65 Patients were given oral cannabidiol at 2-5 mg/kg per day, up-titrated until into

66 Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD

67 by cannabidiol (CBD), termed axially chiral cannabidiols (axCBDs).

68 Remarkably, conolidine and cannabidiol both inhibited Cav2.2, providing a glimpse i

69 e and exposure to 9-tetrahydrocannabinol and cannabidiol by quantifying levels of their metabolites i

70 Interestingly, we found that cannabidiol can preferentially target resurgent sodium c

71 ddition, cannabis-derived compounds (such as cannabidiol) can influence eCBs and S1P signaling, calli

72 binoids Delta(9)-tetrahydrocannabinol (THC), cannabidiol, cannabichromene, and cannabinol is presente

73 binol (Delta(9)-THC), Delta(8)-THC, exo-THC, cannabidiol, cannabichromene, cannabinol, and cannabiger

74 aration of seven cannabinoids (cannabigerol, cannabidiol, cannabinol, delta-9-tetrahydrocannabinol, d

75 Furthermore, the abnormal-cannabidiol (CBD) analog trans-4-[3-methyl-6-(1-methylet

76 Cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC) hav

77 Two were previously known, cannabidiol (CBD) and cannabidivarin (CBDV), whereas the

78 ues explored preclinical interventions using cannabidiol (CBD) and clobazam, opening the way to a cur

79 -2 and CP55,940), and two phytocannabinoids (cannabidiol (CBD) and Delta(9)-tetrahydrocannabinol (THC

80 etrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD) and in one instance, the metabolite 11

81 Floral concentrations of medicinal cannabidiol (CBD) and terpenoids were not affected by Se

82 bis and its major non-intoxicating component cannabidiol (CBD) as a treatment for mental health and n

83 ed to assess the effectiveness and safety of cannabidiol (CBD) as an analgesic for patients with emer

84 inoids delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both have immunosuppressive effects; a

85 There is some evidence that cannabidiol (CBD) can induce cell death and increases th

86 clinical laboratory studies have shown that cannabidiol (CBD) can sometimes attenuate or exacerbate

87 tudies using tetrahydrocannabinol (THC), THC:cannabidiol (CBD) combination, and CBD.

88 Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations decreased significantly

89 noids Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attri

90 Here we show that cannabidiol (CBD) effectively reduced seizures and autis

91 ch in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties.

92 Cannabidiol (CBD) has anxiolytic and antidepressant prop

93 Cannabidiol (CBD) has been approved for the treatment of

94 Cannabidiol (CBD) has been shown by our laboratory to at

95 The nonpsychoactive phytocannabinoid cannabidiol (CBD) has been shown to have analgesic effec

96 odest depolarizations.SIGNIFICANCE STATEMENT Cannabidiol (CBD) has been shown to inhibit pain in vari

97 The major non-psychotropic phytocannabinoid cannabidiol (CBD) has emerged as an anti-seizure medicat

98 Cannabidiol (CBD) has gained attention as a therapeutic

99 tetrahydrocannabinol (THC) and low levels of cannabidiol (CBD) have been shown to underlie neuropsych

100 The reported characteristics of cannabidiol (CBD) have encouraged significant growth in

101 Products containing cannabinoids such as cannabidiol (CBD) have proliferated since 2018, when the

102 nt of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in Cannabis sativa L. is an ever-incre

103 ng recently approved formulations containing cannabidiol (CBD) in this patient group.

104 investigations have established the role of cannabidiol (CBD) in treating epilepsy and seizures and

105 Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in ce

106 Cannabidiol (CBD) is a compound found in the cannabis pl

107 Cannabidiol (CBD) is a natural nonpsychotropic cannabino

108 Cannabidiol (CBD) is a non-psychoactive component of mar

109 Cannabidiol (CBD) is being investigated as a treatment f

110 Cannabidiol (CBD) is the subject of considerable scienti

111 Cannabidiol (CBD) is thought to have multiple biological

112 rahydroxycannabinol (THC) or nonpsychotropic cannabidiol (CBD) is via the attenuation of this formati

113 Cannabidiol (CBD) is widely used and believed to be non-

114 udies outside of oncology has suggested that cannabidiol (CBD) may have anxiolytic effects without ne

115 y volunteers suggest that pre-treatment with cannabidiol (CBD) may reduce these effects, but others d

116 Delta(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) occur naturally in marijuana (Cannabis

117 with increased crash risk, but the effect of cannabidiol (CBD) on driving is unclear.

118 s study, we have investigated the effects of cannabidiol (CBD) on myocardial dysfunction, inflammatio

119 r mixtures containing high concentrations of cannabidiol (CBD) or VEA.

120 e published essential medicinal chemistry of cannabidiol (CBD) provides evidence that the popularizat

121 oaches was sparked by preclinical studies of cannabidiol (CBD) that led to the 2018 US Food and Drug

122 The ratio of cannabidiol (CBD) to cannabidiolic acid (CBDA) was close

123 ily through 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) via cannabinoid receptors, which may b

124 seeds or popular varieties to achieve higher cannabidiol (CBD) yields, with seeds costing approximate

125 paration comprising equal amounts of THC and cannabidiol (CBD)) to mice bearing BRAF wild-type melano

126 ted 10.5% of the US population reports using cannabidiol (CBD), a chemical compound extracted from ca

127 Cannabidiol (CBD), a chemical found in the Cannabis sati

128 Cannabidiol (CBD), a constituent of cannabis with few ps

129 Cannabidiol (CBD), a constituent of the Cannabis sativa

130 d carriers (NLCs) as a potential vehicle for cannabidiol (CBD), a lipophilic molecule with great pote

131 Cannabidiol (CBD), a major non-psychoactive phytocannabi

132 t systemic and intrathecal administration of cannabidiol (CBD), a major nonpsychoactive component of

133 Cannabidiol (CBD), a major phytocannabinoid constituent

134 Cannabidiol (CBD), a non-euphoric component of cannabis,

135 Cannabidiol (CBD), a non-psychoactive cannabinoid of cli

136 Cannabidiol (CBD), a non-psychotropic constituent of can

137 Cannabidiol (CBD), a nonintoxicating cannabinoid, is und

138 This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, t

139 Here, we examined the effects of cannabidiol (CBD), a nonpsychoactive constituent of cann

140 Cannabidiol (CBD), a nonpsychotropic, nontoxic compound

141 Nausea can be alleviated with cannabidiol (CBD), a primary component of cannabis that

142 ncluding delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG).

143 55,940, Delta(9)-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+CBD (1:1), and compared betwe

144 etrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), and the metabolites 11-nor-9-carboxy-

145 -tetrahydrocannabinol (THC) and its sibling, cannabidiol (CBD), are produced by the same Cannabis pla

146 igh-potency cannabis flower with and without cannabidiol (CBD), as well as cannabis concentrates to c

147 onversion of cannabidiolic acid (CBD-A) into cannabidiol (CBD), cannabichromenic acid (CBC-A) into ca

148 100 additional phytocannabinoids, including cannabidiol (CBD), cannabidivarin (CBDV), Delta(9)-tetra

149 n non-psychoactive phytocannabinoids, namely cannabidiol (CBD), cannabigerol (CBG), and cannabichrome

150 e that three nonpsychotomimetic cannabinoids-cannabidiol (CBD), cannabigerol (CBG), and cannabinol (C

151 investigated the hepatotoxicity potential of Cannabidiol (CBD), Cannabinol (CBN), Cannabichromene (CB

152 The cannabis-derived phytochemical, cannabidiol (CBD), has been shown to have pharmacotherap

153 ives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therape

154 pic phytocannabinoid of Cannabis sativa, (-)-cannabidiol (CBD), on human sebaceous gland function and

155 s of axially chiral cannabinoids inspired by cannabidiol (CBD), termed axially chiral cannabidiols (a

156 Cannabidiol (CBD), the non-psychoactive compound isolate

157 Cannabidiol (CBD), the non-psychotropic therapeutically

158 Demand for cannabidiol (CBD), the predominant cannabinoid in hemp (

159 Cannabidiol (CBD), the second most abundant of the activ

160 lta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD), the two major derivatives of cannabis

161 ve effects of a nonpsychotropic cannabinoid, cannabidiol (CBD), were examined in streptozotocin-induc

162 s are Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which affect the endocannabinoid syst

163 phytochemical component of marijuana called cannabidiol (CBD), which possesses promising therapeutic

164 p has led to wide commercial availability of cannabidiol (CBD)-containing products.

165 se active pharmaceutical ingredient (API) is cannabidiol (CBD).

166 r hemp, produces a non-psychoactive compound cannabidiol (CBD).

167 concentrated on its less intoxicating isomer cannabidiol (CBD).

168 tent of 18.74% (6.12%) THC and 1.46% (3.37%) cannabidiol (CBD).

169 are Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD).

170 ssing ambiguities surrounding the binding of cannabidiol (CBD).

171 ions between/among Delta9-THC, caffeine, and cannabidiol (CBD).

172 o-y Coupling was partly restored by cannabidiol (CBD).

173 theta-gamma Coupling was partly restored by cannabidiol (CBD).

174 ding Delta(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD).

175 t is the primary nonpsychoactive constituent cannabidiol (CBD).

176 ease of the potentially therapeutic compound cannabidiol (CBD).

177 and rhizosphere microbial communities of two cannabidiol (CBD; Sweet Sensi and Cherry Wine) and two f

178 (-)-Cannabidiol ((-)-CBD) is a candidate muOR NAM.

179 ost important phytocannabinoids, namely, (-)-cannabidiol (-CBD), from inexpensive and readily availab

180 oid contents (tetrahydrocannabinol, THC; and cannabidiol, CBD), along with real-time ratings of healt

181 k activity profiles evoked by conolidine and cannabidiol closely matched that of omega-conotoxin CVIE

182 as demonstrated using 11 drugs (amphetamine, cannabidiol, cocaine, codeine, heroine, methamphetamine,

183 with high THC concentrations and negligible cannabidiol concentrations is associated with an increas

184 The cannabidiol content has decreased on average from ~.28%

185 potential protection from harmful effects by cannabidiol continues to increase but is not definitive.

186 ydrogen (NADH), Fostamatinib, Glutamic acid, Cannabidiol, Copper, and Zinc in DrugBank identified via

187 These findings suggest that cannabidiol could be exerting its anticonvulsant effects

188 ence of two pesticides, a plasticizer, and a cannabidiol degradation product in some of the samples.

189 lerability, and acceptability of transdermal cannabidiol delivery.

190 on (SPME) is applied to the determination of cannabidiol, delta 8-tetrahydrocannabinol (delta 8-THC),

191 A catalytic hydrogenation of cannabidiol derivatives known as phenylcyclohexenes was

192 enous eCBs and S1P-as well as with exogenous cannabidiol-described here offers a compelling example o

193 We also demonstrated that cannabidiol evoked a concentration-dependent release of

194 Moreover, the cannabidiol-evoked CGRP release depended on extracellula

195 repetitive stimulation studies, to show that cannabidiol-evoked CGRP release is mediated, at least in

196 that TRPV2 may comprise a mechanism whereby cannabidiol exerts its clinically beneficial effects in

197 Finally, cannabidiol exposure led to a decrease in the levels of

198 It is noteworthy that cannabidiol exposure led to an increase in reactive oxyg

199 From a mechanistic standpoint, cannabidiol exposure resulted in activation of caspase-8

200 to determine if the anti-seizure effects of cannabidiol extend to other forms of epilepsy, to overco

201 We studied cannabidiol for the treatment of drug-resistant seizures

202 andomised controlled trials of plant-derived cannabidiol for treatment of Lennox-Gastaut syndrome and

203 he ratio of Delta(9)-tetrahydrocannabinol to cannabidiol from 14 times in 1995 to ~80 times in 2014.

204 cebo (adjusted median difference between the cannabidiol group and the placebo group in change in sei

205 bal Impression of Change scale in 62% of the cannabidiol group as compared with 34% of the placebo gr

206 events that occurred more frequently in the cannabidiol group than in the placebo group included dia

207 red in 50.4% (63 of 125 participants) of the cannabidiol group vs 41.3% (26 of 63 participants) in th

208 were more withdrawals from the trial in the cannabidiol group.

209 23.6%), and occurred at similar rates in the cannabidiol groups.

210 In contrast, administration of cannabidiol had no such effect.

211 ments show that the combination of 2-APB and cannabidiol has a synergetic effect on TRPV2 activation,

212 Efficacy of cannabidiol has been demonstrated in seizures associated

213 to target voltage-gated sodium channels and cannabidiol has recently received attention for its pote

214 Cannabidiol has shown efficacy in randomized clinical tr

215 The CBs, Delta(9)-THC, cannabidiol, HU-210, and CP 55,940 caused alcohol-like e

216 irable products, including cannabielsoin and cannabidiol hydroxyquinone.

217 Cannabidiol improved 50% reduction of seizures (0.59 (0.

218 s detected in liver, kidney, and adipose and cannabidiol in all tissues.

219 yme-linked immunosorbent assay-like assay of cannabidiol in body fluids with a detection limit of ~0.

220 evel evidence for the efficacy and safety of cannabidiol in the most common form of drug-resistant ep

221 For epilepsy, cannabidiol increased risk of diarrhoea (2.25 (1.33 to 3

222 Furthermore, cannabidiol-induced apoptosis and reactive oxygen specie

223 d more potent than (+)-cannabidiol; abnormal-cannabidiol is a full agonist.

224 The phytocannabinoid (-)-cannabidiol is a partial agonist, being approximately 40

225 Cannabidiol is effective in people with epilepsy.

226 Exposure of leukemia cells to cannabidiol led to cannabinoid receptor 2 (CB2)-mediated

227 hondria was further suggested as exposure to cannabidiol led to loss of mitochondrial membrane potent

228 However, there is first evidence that cannabidiol may ameliorate psychotic symptoms with a sup

229 ally occurring, nonpsychotropic cannabinoid, cannabidiol, may be a potentially useful therapeutic age

230 2.49 [1.31] seizures per 28 days) and 195-mg cannabidiol (mean [SD] 2.51 [1.15] seizures per 28 days;

231 95% CI, -0.175 to 0.203; P = .89) or 390-mg cannabidiol (mean [SD] 2.59 [1.12] seizures per 28 days;

232 Our findings suggest that cannabidiol might reduce seizure frequency and might hav

233 psychopathological and cognitive effects of cannabidiol, no published data are available.

234 e separations, exemplified here by enriching cannabidiol oil, they achieved one order of magnitude fa

235 ate our findings, we examined the effects of cannabidiol on endogenous sodium currents from striatal

236 then examined the effects of anandamide and cannabidiol on peak transient and resurgent currents fro

237 effects of the nonpsychoactive cannabinoid, cannabidiol, on the induction of apoptosis in leukemia c

238 rast, anti-inflammatory cannabinoids such as cannabidiol or delta-9-tetrahydrocannabinol decreased th

239 ed a combination of the following keywords: (cannabidiol OR epidiolex) AND (epilepsy OR seizures).

240 and to uncover the exact mechanisms by which cannabidiol or other exogenous and endogenous cannabinoi

241 ized (1:1:1) to 195-mg or 390-mg transdermal cannabidiol or placebo twice daily for 12 weeks, after w

242 of Delta9-tetrahydrocannabinol and 80 mg of cannabidiol) or placebo with standardized psychosocial i

243 ta-9-tetrahydrocannabiol (THC), decreases in cannabidiol, or both, have occurred.

244 ce to consume Delta(9)-tetrahydrocannabinol, cannabidiol, or morphine ad libitum.

245 nd drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg per kilogra

246 of all types was significantly reduced with cannabidiol (P=0.03), but there was no significant reduc

247 16 binding location is distinct from that of cannabidiol, partially overlapping with the binding site

248 -catalyzed intramolecular cyclization of the cannabidiol precursor.

249 study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of 9-

250 with the pharmacology of the novel "abnormal-cannabidiol" receptor or a related orphan G protein-coup

251 s well as from the WIN and abn-CBD (abnormal-cannabidiol) receptors, two recently identified cannabin

252 Moreover, current clamp recordings show that cannabidiol reduces overall action potential firing of s

253 Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsiv

254 a(9)-tetrahydrocannabinol-rich (CAN(THC)) or cannabidiol-rich (CAN(CBD)) whole-plant cannabis extract

255 ort the crystal structure of a dual-nanobody cannabidiol-sensing system, in which the ligand promotes

256 gration by antagonizing the CB2 and abnormal-cannabidiol-sensitive receptors, respectively.

257 fect of 2-AG occurs through CB2 and abnormal-cannabidiol-sensitive receptors, with subsequent activat

258 draw close parallels among the dual-nanobody cannabidiol sensor, the auxin perception complex, and th

259 Cannabidiol showed the greatest reduction of the seizure

260 In addition, cannabidiol significantly inhibits the invasion of gliob

261 Cannabidiol significantly reduced TSC-associated seizure

262 rthermore, we show that a nontoxic compound, cannabidiol, significantly downregulates Id-1 gene expre

263 [26%]), which occurred more frequently with cannabidiol than placebo.

264 Cannabidiol, THC and several synthetic cannabinoids all

265 cannabinoids (delta9-tetrahydrocannabinol + cannabidiol; THC + CBD) for 15 days, and the stressed ma

266 dipose was selected as the target tissue and cannabidiol the marker residue.

267 Cannabidiol, the most abundant nonpsychoactive constitue

268 CP55940, Delta(9)-tetrahydrocannabinol, and cannabidiol, thus suggesting that the phenomenon is not

269 pare network activity profiles of conolidine/cannabidiol to a series of well-studied compounds with k

270 for the therapeutic development of medicinal cannabidiol to address the current opioid abuse crisis.

271 Application of conolidine/cannabidiol to cultured neuronal networks altered networ

272 We aimed to establish whether addition of cannabidiol to existing anti-epileptic regimens would be

273 e.g., MDMA-assisted psychotherapy, ketamine, cannabidiol, transcranial magnetic stimulation).

274 Furthermore, cannabidiol treatment led to a significant decrease in t

275 It is important to note that cannabinol and cannabidiol, two nonpsychotropic ingredients present in

276 ad severe adverse events possibly related to cannabidiol use, the most common of which was status epi

277 ine in number of TSC-associated seizures for cannabidiol vs placebo during the treatment period.

278 Moreover, its opposite isomer (+)-cannabidiol was also successfully synthesized from S-(-)

279 d with whole-cell patch clamp and conolidine/cannabidiol was applied.

280 Among these, cannabidiol was found to be the most robust and potent (

281 Cannabidiol was more protective against glutamate neurot

282 2 weeks of follow-up after the first dose of cannabidiol were included in the safety and tolerability

283 Both doses of transdermal cannabidiol were well tolerated and safe.

284 By contrast, cannabidiol, which is a non-intoxicating and potentially

285 -based heterodimerization systems induced by cannabidiol with high ligand selectivity.

286 A is considered the endogenous equivalent of cannabidiol, with increased serum levels believed to hav